NCT03475251: A Study of CS1003 in Subjects With Advanced Solid Tumors

NCT03475251
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic or untreated CNS or brain metastasis
https://ClinicalTrials.gov/show/NCT03475251

Comments are closed.

Up ↑